Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at irinotecan and carboplatin for small cell lung cancer

Overview

Cancer types:

Lung cancer, Small cell lung cancer

Status:

Results

Phase:

Phase 1

Details

This trial looked at carboplatin, with different doses of irinotecan, for people with extensive small cell lung cancer.

Doctors usually treat small cell lung cancer with 2 chemotherapy drugs called etoposide and either cisplatin or carboplatin. Lung cancer often responds well to these drugs, but unfortunately it usually comes back later.

We know from research that irinotecan may also help people with small cell lung cancer. Doctors thought the combination of irinotecan and carboplatin might have been a better treatment for small cell lung cancer.

The aims of this trial were to find out

  • The best dose of irinotecan to give with carboplatin

  • What the side effects of this drug combination were

  • How well this treatment worked

Recruitment start: 1 September 2004

Recruitment end: 21 September 2010

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Prof Christian Ottensmeier

Supported by

Experimental Cancer Medicine Centre (ECMC)

University Hospital Southampton NHS Foundation Trust

University of Southampton

Last reviewed: 13 Jan 2016

CRUK internal database number: 670

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.